National Policy on Traditional Medicine and Regulation of Herbal Medicines - Report of a WHO Global Survey
(2005; 168 pages) Voir le document au format PDF
Table des matières
Afficher le documentAcknowledgements
Afficher le documentExecutive summary
Afficher le documentAcronyms, abbreviations and definitions
Afficher le documentWHO Regions
Ouvrir ce répertoire et afficher son contenu1. Introduction
Ouvrir ce répertoire et afficher son contenu2. National policy on traditional medicine and complementary/alternative medicine
Fermer ce répertoire3. The regulatory situation of herbal medicines
Afficher le document3.1 Law or regulation on herbal medicines
Afficher le document3.2 Regulatory status of herbal medicines
Afficher le document3.3 Claims
Afficher le document3.4 Pharmacopoeias
Afficher le document3.5 Monographs on herbal medicines
Afficher le document3.6 Manufacture of herbal medicines
Afficher le document3.7 Safety and herbal medicines
Afficher le document3.8 Registration system for herbal medicines
Afficher le document3.9 Herbal medicines and the essential drug list
Afficher le document3.10 Post marketing surveillance of herbal medicines
Afficher le document3.11 The sale of herbal medicines
Afficher le document3.12 Annual market sales of herbal medicines
Ouvrir ce répertoire et afficher son contenu4. Member States, WHO and herbal medicines
Ouvrir ce répertoire et afficher son contenu5. Country summaries
Afficher le documentReferences
Afficher le documentAnnex 1. Text of survey instrument
 

3.10 Post marketing surveillance of herbal medicines

Countries were first asked whether they had a post marketing surveillance system for herbal medicines. If countries responded “yes”, the next question asked whether there is a national system to monitor adverse effects of herbal medicines. If such a system exists, the date of establishment was requested. If the Member State reported that a post marketing surveillance system for herbal medicines did not exist, the next question asked if there are plans to establish such a system.

A total of 114 countries answered the first question regarding the existence of a post-marketing surveillance system for herbal medicines. Fifty-nine countries, or 42%, reported that they had such a system (Figure 38), with many indicating in a comment that the surveillance system is the same as for conventional pharmaceuticals.


Figure 38. Post-marketing surveillance system for herbal medicines

Of those countries that reported the existence of a post marketing surveillance system, 53, or 90%, reported that they also had a national system to monitor adverse effects of herbal medicines (Figure 39). Of these 53 countries, 37 provided information on the year of establishment of national systems to monitor adverse effects of herbal medicines. The majority have been founded in the last 15 years (Figure 40).


Figure 39. National system to monitor adverse effects relating to herbal medicines


Figure 40. Number of Member States with a national system to monitor adverse effects relating to herbal medicines, by year

vers la section précédente
vers la section suivante
 
 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 20 mars 2014